Ascletis Pharma (Ascletis-B, HKEX: 01672) has filed a Next Day Disclosure Return outlining the latest activity under its 2025 share-repurchase mandate.​

Key Facts

• Issued Share Capital Unchanged: As of 10 June 2026, Ascletis has 1.061 billion ordinary shares in issue (excluding 7.08 million treasury shares), identical to the previous day’s balance.

• 10 June Transaction: The company bought back 200,000 shares on the Hong Kong Stock Exchange, paying between HKD 9.75 and HKD 10.15 per share. The aggregate consideration was HKD 1.9996 million, equivalent to 0.02% of shares in issue. All repurchased shares are earmarked for cancellation.

• Accumulated Repurchases: Since the mandate was approved on 22 May 2025, Ascletis has acquired 7.69 million shares, representing 0.80% of the share count at the mandate date. Of these, 7.19 million shares remained uncancelled as at 10 June 2026.

• Remaining Capacity: The mandate allows up to 96.28 million shares to be repurchased. After the latest transaction, 88.60 million shares—approximately 9.43% of current issued shares—remain available for future buybacks.

• Moratorium on New Issues: In line with HKEX rules, Ascletis is restricted from issuing new shares or selling treasury shares until 10 July 2026 (30 days after the latest purchase).

The company confirmed all buybacks complied with Hong Kong Main Board Rule 10.06 and there have been no material changes to the explanatory statement dated 29 April 2025.